Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 383.14%.

  • Coherus Oncology's EBITDA Margin rose 3910800.0% to 383.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.36%, marking a year-over-year increase of 1691900.0%. This contributed to the annual value of 41.83% for FY2024, which is 371600.0% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's EBITDA Margin is 383.14%, which was up 3910800.0% from 443.59% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's EBITDA Margin ranged from a high of 17.16% in Q4 2024 and a low of 2937.05% during Q1 2024
  • Moreover, its 5-year median value for EBITDA Margin was 134.62% (2022), whereas its average is 353.2%.
  • In the last 5 years, Coherus Oncology's EBITDA Margin tumbled by -27281900bps in 2024 and then soared by 23391400bps in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's EBITDA Margin stood at 53.91% in 2021, then tumbled by -111bps to 113.54% in 2022, then skyrocketed by 34bps to 75.29% in 2023, then soared by 123bps to 17.16% in 2024, then plummeted by -2333bps to 383.14% in 2025.
  • Its EBITDA Margin stands at 383.14% for Q3 2025, versus 443.59% for Q2 2025 and 597.91% for Q1 2025.